Use

InVisionFirst®‑Lung Liquid Biopsy is a ctDNA‑based next‑generation sequencing assay designed to detect genomic alterations—including SNVs, indels, copy number variations, splice variants, and gene fusions—in patients with advanced non‑small cell lung cancer (NSCLC), enabling therapy selection when tissue is limited or unavailable. It provides molecular insights aligned with guideline‑recommended genomic drivers for targeted therapies with results delivered within seven calendar days. ([ir.neogenomics.com](https://ir.neogenomics.com/news-events/press-releases/detail/146/neogenomics-enters-strategic-collaboration-with-inivata-to-commercialize-invisionfirstr-lung-liquid-biopsy-test?utm_source=openai))